- Cambridge MA, US Joel Moore - Lexington MA, US Nicholas Robert Perl - Somerville MA, US Rajesh R. Iyengar - West Newton MA, US Ara Mermerian - Waltham MA, US Thomas Wai-Ho Lee - Lexington MA, US Colleen Hudson - Arvada CO, US Glen Robert Rennie - Somerville MA, US Lei Jia - San Diego CA, US Paul Allan Renhowe - Sudbury MA, US Timothy Claude Barden - Gibsonia PA, US Xiang Y. Yu - Acton MA, US James Edward Sheppeck - Newtown PA, US Karthik Iyer - Cambridge MA, US Joon Jung - Newton MA, US George Todd Milne - Brookline MA, US Kimberly Kafadar Long - Boston MA, US Mark G. Currie - Sterling MA, US
Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
- Cambridge MA, US James Edward Sheppeck - Newtown PA, US Takashi Nakai - Newton MA, US Karthik Iyer - Cambridge MA, US Nicholas Robert Perl - Somerville MA, US Glen Robert Rennie - Somerville MA, US Mark G. Currie - Boston MA, US Kimberly Kafadar Long - Boston MA, US George Todd Milne - Brookline MA, US Rajesh R. Iyengar - West Newton MA, US
The present patent application discloses at least the compounds according to Formula l shown below, or pharmaceutically acceptable salts thereof, wherein ring,, J, J,, X, X, J, R, and W are as defined herein. These compounds are useful as simulators of soluble sGC.
- Cambridge MA, US Joel Moore - Lexington MA, US Nicholas Robert Perl - Somerville MA, US Rajesh R. Iyengar - West Newton MA, US Ara Mermerian - Waltham MA, US Thomas Wai-Ho Lee - Lexington MA, US Colleen Hudson - Malden MA, US Glen Robert Rennie - Somerville MA, US Lei Jia - San Diego CA, US Paul Allan Renhowe - Sudbury MA, US Timothy Claude Barden - Waltham MA, US Xiang Y. Yu - Acton MA, US James Edward Sheppeck - Newtown PA, US Karthik Iyer - Cambridge MA, US Joon Jung - Newton MA, US George Todd Milne - Brookline MA, US Kimberly Kafadar Long - Boston MA, US Mark G. Currie - Sterling MA, US
Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
Isoform-Specific, Context-Permissive Tgfb1 Inhibitors And Use Thereof
- Cambridge MA, US Abhishek Datta - Boston MA, US Gregory J. Carven - Maynard MA, US Constance Martin - Arlington MA, US Ashish Kalra - Belmont MA, US Kimberly Long - Boston MA, US Alan Buckler - Arlington MA, US
International Classification:
A61K 39/395 C07K 16/22 G01N 33/574 A61P 35/04
Abstract:
Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGFβ1 in the treatment of disease that involve TGFβ1 dysregulation.
- Cambridge MA, US Joel Moore - Lexington MA, US Nicholas Robert Perl - Somerville MA, US Rajesh R. Iyengar - West Newton MA, US Ara Mermerian - Waltham MA, US Thomas Wai-Ho Lee - Lexignton MA, US Colleen Hudson - Malden MA, US Glen Robert Rennie - Somerville MA, US James Jia - Belmont MA, US Paul Allan Renhowe - Sudbury MA, US Timothy Claude Barden - Salem MA, US Xiang Y. Yu - Acton MA, US James Edward Sheppeck - Newtown PA, US Karthik Iyer - 02140 MA, US Joon Jung - Newton MA, US George Todd Milne - Brookline MA, US Kimberly Kafadar Long - Boston MA, US Mark G. Currie - Boston MA, US
Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGFβ1, LTBP1-TGFβ1, LTBP3-TGFβ1, and/or LRRC33-TGFβ1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGFβ1 activity, and treating subjects suffering from TGFβ1-related disorders, such as cancer and fibrosis.
Isoform-Specific, Context-Permissive Tgfb1 Inhibitors And Use Thereof
- Cambridge MA, US Abhishek Datta - Boston MA, US Gregory J. Carven - Maynard MA, US Constance Martin - Arlington MA, US Ashish Kalra - Belmont MA, US Kimberly Long - Boston MA, US Alan Buckler - Arlington MA, US
International Classification:
A61K 39/395 C07K 16/22 G01N 33/574 A61P 35/04
Abstract:
Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGFβ1 in the treatment of disease that involve TGFβ1 dysregulation.
- Cambridge MA, US Joel MOORE - Lexington MA, US Nicholas Robert PERL - Somerville MA, US Rajesh R. IYENGAR - West Newton MA, US Ara MERMERIAN - Waltham MA, US Thomas Wai-Ho LEE - Lexington MA, US Colleen HUDSON - Denver CO, US Glen Robert RENNIE - Somerville MA, US James JIA - Belmont MA, US Paul Allan RENHOWE - Sudbury MA, US Timothy Claude BARDEN - Salem MA, US Xiang Y. YU - Acton MA, US James Edward SHEPPECK - Newtown PA, US Karthik IYER - Cambridge MA, US Joon JUNG - Newton MA, US George Todd MILNE - Brookline MA, US Kimberly Kafadar LONG - Boston MA, US Mark G. CURRIE - Boston MA, US
Assignee:
Ironwood Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 31/506 A61K 45/06
Abstract:
Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
Name / Title
Company / Classification
Phones & Addresses
Kimberly Long Director
WAYLAND SWIMMING AND TENNIS CLUB, INC
PO Box 315, Wayland, MA 01778 106 Concord Rd, Wayland, MA 01778
Kimberly Long
TWO FAT GUYS BAR-B-Q, LLC
Kimberly R Long
PHOENIX PROPERTIES LTD
Kimberly F Long Secretary
KPM INTERNATIONAL ASSOCIATE, INC
241 Boston Post Rd SUITE 4, Wayland, MA 01778 106 Concord Rd, Wayland, MA 01778